Berney C R, Yang J L, Fisher R J, Russell P J, Crowe P J
Department of Surgery, University of New South Wales, Randwick, Australia.
Anticancer Res. 1998 Mar-Apr;18(2A):973-7.
We undertook a retrospective study to investigate the correlation between the expression of vascular endothelial growth factor (VEGF) and urokinase-type plasminogen activator (u-PA) proteins with progression of colorectal carcinoma (CRC). Immunohistochemical analyses using antibodies against VEGF and u-PA were carried out on archival specimens of 58 human colon carcinomas, 30 liver secondaries and 20 adenomas. Expression of VEGF was significantly reduced in the metastatic liver tumours compared with primary ones (Wilcoxon test, P = 0.002), suggesting VEGF activity to be secondarily down-regulated once the tumour cells reach the hepatic parenchyma. There was no strong evidence from our data that the level of VEGF or u-PA in the primary tumour could predict risk of liver metastasis or survival duration. VEGF and u-PA expression were positively correlated in primary CRC suggesting that both proteins may interact in vivo (chi-square test, P = 0.019) in tumour progression.
我们进行了一项回顾性研究，以调查血管内皮生长因子（VEGF）和尿激酶型纤溶酶原激活剂（u-PA）蛋白的表达与结直肠癌（CRC）进展之间的相关性。使用抗VEGF和u-PA抗体对58例人类结肠癌、30例肝转移瘤和20例腺瘤的存档标本进行了免疫组织化学分析。与原发性肝肿瘤相比，转移性肝肿瘤中VEGF的表达显著降低（Wilcoxon检验，P = 0.002），这表明一旦肿瘤细胞到达肝实质，VEGF活性会继发性下调。我们的数据没有强有力的证据表明原发性肿瘤中VEGF或u-PA的水平可以预测肝转移风险或生存时间。原发性结直肠癌中VEGF和u-PA的表达呈正相关，这表明这两种蛋白在肿瘤进展过程中可能在体内相互作用（卡方检验，P = 0.019）。
